WESTBOROUGH, MA-Biotech firm RenaMed Biologics Inc. will move its corporate headquarters from Lincoln, RI to this Massachusetts city this summer under a long-term lease on 100,000 sf of office and research space. The move will put the company closer to its partner, biotech giant Genzyme Corp.

The three-story 20 Walkup Dr. building, which the firm will occupy fully, will serve both as RenaMed’s headquarters and the commercial manufacturing facility for its Renal Bio-Replacement Therapy products for Acute Renal Failure. Terms of the long-term lease were not disclosed.

Joe Flynn, vice president at NAI Hunneman Commercial, represented RenaMed Biologics. Brian McKenzie, John Lashar and Paul Leone of Richards Barry Joyce & Partners represented the building’s landlord, Campanelli Cos..

Richard Andrews, senior business manager for the firm, tells GlobeSt.com that the company selected the site because it offered a strong production component with a clean-room infrastructure that can handle the company’s increasing operational needs.

“The space has a lot to offer,” Andrews says of the building, formerly occupied by Zygo TeraOptix Inc. “Clean room facilities are essential for that business and the site was equipped with excellent clean-room facilities.”

The firm plans to invest several million dollars to rehab the facility in the second quarter of 2006, he adds. RenaMed’s current Lincoln headquarters, which was initially developed as a pilot manufacturing facility in 2001, will continue to operate as a manufacturing facility and development lab.

Andrews says the move, sparked by the firm’s rapid growth, will bring the company closer to the Bay State’s biotech core and put RenaMed just down the street from Genzyme, which it partnered with in September under a joint development and commercialization program. Under that agreement, RenaMed will be responsible for establishing the first US manufacturing facility on a Genzyme product to treat acute renal failure.

The Westborough relocation will also put RenaMed in the midst of Boston’s suburban biotech boom and allow the firm to tap into the region’s high-tech labor force, Andrews says.

Want to continue reading?
Become a Free ALM Digital Reader.

Once you are an ALM digital member, you’ll receive:

  • Unlimited access to GlobeSt and other free ALM publications
  • Access to 15 years of GlobeSt archives
  • Your choice of GlobeSt digital newsletters and over 70 others from popular sister publications
  • 1 free article* every 30 days across the ALM subscription network
  • Exclusive discounts on ALM events and publications

*May exclude premium content
Already have an account?


© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.


GlobeSt Net Lease Spring 2024Event

This conference brings together the industry's most influential & knowledgeable real estate executives from the net lease sector.

Get More Information


Join GlobeSt

Don't miss crucial news and insights you need to make informed commercial real estate decisions. Join GlobeSt.com now!

  • Free unlimited access to GlobeSt.com's trusted and independent team of experts who provide commercial real estate owners, investors, developers, brokers and finance professionals with comprehensive coverage, analysis and best practices necessary to innovate and build business.
  • Exclusive discounts on ALM and GlobeSt events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com.

Already have an account? Sign In Now
Join GlobeSt

Copyright © 2024 ALM Global, LLC. All Rights Reserved.